Our preliminary data indicate that miR-107 plays an important role in AD pathogenesis. Fibrates (PPAR agonists) increase miR-107 expression, and down-regulated BACE1 protein, an essential enzyme contributing to AD, in cultured H4 cells. We plan to test our hypotheses and evaluate a potential therapy for Alzheimer's disease (AD) based on this novel microRNA (miRNA) pathway. Preclinical work in this area using animal models of AD has been thwarted by the species-specific hepatotoxicity not seen in humans. Thus, human clinical trials are necessary to test this important hypothesis on the disease modifying properties of fibrates in AD. Specifically, we propose an evaluation of the safety and efficacy of gemfibrozil administration on micro-RNA modulation of AD mechanisms in a parallel-design, double- blind, placebo-controlled study. We will evaluate both safety and target engagement of miR- 107 by gemfibrozil as well as alterations in relevant AD biomarkers. Gemfibrozil is a safe, orally- administered, FDA-approved drug for treatment of hyperlipidemia in aged individuals. The FDA has indicated IND exemption status for these studies. This study is designed to provide the foundation for future large-scale Phase II &III studies of fibrates in AD and AD prevention trials and represents the first attempt we are aware of designed to modulate disease progression in AD through influences on novel micro-RNA pathways. As such the proposed study represents a cutting-edge, data-driven, exploration of a novel disease relevant pathway that may hold promise for our global efforts targeting this major health priority among developing and developed nations.

Public Health Relevance

Widespread recognition of the current and projected impact of the AD epidemic has spurred research into novel drug discovery efforts. This proposal seeks to further progress in this area, investigating the novel actions of PPAR agonists as a disease modifying therapy in AD through their modulation of novel miRNA pathways that influence A production, repurposing an existing drug therapy. As such, the proposed study represents a cutting-edge, data-driven, low-cost, exploration of a novel disease relevant pathway that may hold promise for our global efforts targeting this major health priority among developing and developed nations.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project (R01)
Project #
1R01AG042419-01A1
Application #
8504030
Study Section
Special Emphasis Panel (ZRG1-BBBP-V (55))
Program Officer
Ryan, Laurie M
Project Start
2013-07-15
Project End
2016-06-30
Budget Start
2013-07-15
Budget End
2014-06-30
Support Year
1
Fiscal Year
2013
Total Cost
$486,839
Indirect Cost
$134,172
Name
University of Kentucky
Department
Neurology
Type
Schools of Medicine
DUNS #
939017877
City
Lexington
State
KY
Country
United States
Zip Code
40506
Niedowicz, Dana M; Özcan, Sabire; Nelson, Peter T (2018) Glimepiride Administered in Chow Reversibly Impairs Glucose Tolerance in Mice. J Diabetes Res 2018:1251345
Al-Janabi, Omar M; Panuganti, Pradeep; Abner, Erin L et al. (2018) Global Cerebral Atrophy Detected by Routine Imaging: Relationship with Age, Hippocampal Atrophy, and White Matter Hyperintensities. J Neuroimaging 28:301-306
Nelson, Peter T; Wang, Wang-Xia; Janse, Sarah A et al. (2018) MicroRNA expression patterns in human anterior cingulate and motor cortex: A study of dementia with Lewy bodies cases and controls. Brain Res 1678:374-383
Smith, Vanessa D; Bachstetter, Adam D; Ighodaro, Eseosa et al. (2018) Overlapping but distinct TDP-43 and tau pathologic patterns in aged hippocampi. Brain Pathol 28:264-273
Ighodaro, Eseosa T; Abner, Erin L; Fardo, David W et al. (2017) Risk factors and global cognitive status related to brain arteriolosclerosis in elderly individuals. J Cereb Blood Flow Metab 37:201-216
Wang, Wang-Xia; Fardo, David W; Jicha, Gregory A et al. (2017) A Customized Quantitative PCR MicroRNA Panel Provides a Technically Robust Context for Studying Neurodegenerative Disease Biomarkers and Indicates a High Correlation Between Cerebrospinal Fluid and Choroid Plexus MicroRNA Expression. Mol Neurobiol 54:8191-8202
Ighodaro, Eseosa T; Nelson, Peter T; Kukull, Walter A et al. (2017) Challenges and Considerations Related to Studying Dementia in Blacks/African Americans. J Alzheimers Dis 60:1-10
Nho, Kwangsik; Saykin, Andrew J; Alzheimer’s Disease Neuroimaging Initiative et al. (2016) Hippocampal Sclerosis of Aging, a Common Alzheimer's Disease 'Mimic': Risk Genotypes are Associated with Brain Atrophy Outside the Temporal Lobe. J Alzheimers Dis 52:373-83
Nelson, Peter T (2016) Cerebrovascular pathology and Alzheimer's disease. Lancet Neurol 15:895-896
Londin, Eric; Loher, Phillipe; Telonis, Aristeidis G et al. (2015) Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- and tissue-specific microRNAs. Proc Natl Acad Sci U S A 112:E1106-15

Showing the most recent 10 out of 16 publications